# Efficacy and Safety of Primovist in Chinese Patients

> **NCT00526188** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 234 (actual)

## Conditions studied

- Known or Suspected Focal Liver Lesions

## Interventions

- **DRUG:** Gadoxetic Acid Disodium (Primovist, BAY86-4873)

## Key facts

- **NCT ID:** NCT00526188
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2015-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00526188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00526188, "Efficacy and Safety of Primovist in Chinese Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00526188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*